Recombinant Human PILR-alpha Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human PILR-alpha Protein, CF Summary

• Additional Information: His-tag
• Details of Functionality: Measured by its binding ability in a functional ELISA. When recombinant human PANP Fc Chimera is immobilized at 5 μg/mL (100 μL/well), the concentration of Recombinant Human PILR-alpha that produces 50% optimal binding response is approximately 0.4-2 μg/mL.
• Source: Mouse myeloma cell line, NS0-derived human PILR-alpha protein
  Gln20-Thr196 with a C-terminal 6-His tag
• Accession #: CAC01613
• N-terminal Sequence: Gln20 predicted: No results obtained, sequencing might be blocked
  Thr25 (Minor)
• Protein/Peptide Type: Recombinant Proteins
• Gene: PILRA
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 20.9 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 33-40 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS and EDTA.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Reconstitution Instructions: Reconstitute at 100 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human PILR-alpha Protein, CF

• Cell surface receptor FDF03
• FDF03
• inhibitory receptor PILRalpha
• Inhibitory receptor PILR-alpha
• paired immunoglobin-like receptor alpha
• paired immunoglobin-like type 2 receptor alpha
• paired immunoglobulin-like receptor alpha
• paired immunoglobulin-like type 2 receptor alpha
• PILRA
• PILRalpha
• PILR-alpha

Background

PILR-alpha (paired immunoglobulin-like type 2 receptor-alpha; also FDF03) is one of two members that belong to a small family of immunoregulatory Ig-superfamily receptors (1-4). It is a counterpart to PILR-beta , and likely gave rise to the PILR-beta gene through duplication and rearrangement (1). The PILRs represent one of many pairs of Ig-like domain-containing receptors that participate in immune regulation. PILR-alpha and -beta should not be confused with the similarly named PIRs (also paired immunoglobulin-like receptors ), or the functionally-related SIRP and ILT/LILR/CD85/LIR family of receptors (2). While PIRs, ILTs and SIRPs contain three to
six Ig‑like domains in their extracellular region, PILR-alpha and -beta show only one Ig-like region in their extracellular domain (ECD) (1-5). Human PILR-alpha is a monomeric, 55 kDa, 294 amino acid (aa) type I transmembrane (TM) glycoprotein (3-5). It contains a 178 aa ECD (aa 20-197), a 21 aa TM segment, and a long, 85 aa cytoplasmic region (aa 219-303). The ECD shows one V-type Ig-like domain between aa 32-150, while the cytoplasmic region contains two ITIMs (immunoreceptor Tyr-based inhibitory motifs) between aa 267-272 and 296-301. Given that ITIMs are known to interact with phosphatases such as PTPN6 and PTPN11, the presence of these motifs make mouse PILR-alpha an inhibitory receptor. Three potential isoforms for human PILR-alpha have been reported. The first contains a 24 aa substitution for aa 152‑303, a second possesses a 36 aa substitution for aa 264-303, and a third shows a deletion of aa 152-224 (6). The human PILR-alpha ECD shares 43% aa sequence identity with mouse PILR-alpha ECD, and 82% aa sequence identity with the ECD of human PILR-beta (3, 4).

PILR-alpha is expressed by neutrophils, macrophages, monocytes, mast cells, APCs, microglia, neurons, cardiac muscle and renal proximal plus pancreatic duct eipthelium (4, 7, 8). It has multiple binding partners, including CD99 (4, 9), glycoprotein B/gB of HSV-1 (7), PANP (PILR-associated neural protein) (8) and NPDC1 plus collectin-12 (10). Although PILR-alpha and -beta are related through gene duplication and highly similar in their ECD aa sequence, they do not necessarily share the same ligands (or binding partners), as PILR-beta fails to bind to gB and PANP (8, 10). Notably, PILR-alpha binding appears to be dependent upon the presence of a poorly-defined peptide sequence coupled to a sialylated, O-linked carbohydrate motif (5, 9-12). It is unclear what function(s) can be attributed to PILR-alpha . One possibility suggests that in the early stage of an immune response, PILR-beta predominates over PILR-alpha on the APC surface. Ligation of PILR-beta by CD99 induces IL-12 production and immune cell activation. But this ligation also up‑regulates PILR-alpha expression, and subsequent CD99:PILR‑ alpha engagement now promotes IL-27 production, with a concomitant increase in T cell IL-10 production, and a down‑regulation of the inflammatory response (10).

1. Wilson, M.D. et al. (2006) Physiol. Genomics 27:201.
2. Lanier, L.L. (2001) Curr. Opin. Immunol. 13:326.
3. Fournier, N. et al. (2000) J. Immunol. 165:1197.
4. Shiratori, I. et al. (2004) J. Exp. Med. 199:525.
5. Mousseau, D.D. et al. (2000) J. Biol. Chem. 275:4467.
6. SwissProt Accession # Q9UKJ1.
7. Tato, C.M. et al. (2012) PLoS ONE 7:e31680.
8. Satoh, T. et al. (2008) Cell 132:935.
9. Tabata, S. et al. (2008) J. Biol. Chem. 283:8893.
10. Sun, Y. et al. (2012) J. Biol. Chem. 287:15837.
11. Wang, J. et al. (2008) J. Biol. Chem. 180:1686.
12. Arii, J. et al. (2010) J. Virol. 84:10733.

Bioinformatics

• Gene Symbol: PILRA
• Uniprot:
  • CAC01613()